A

Arecor Therapeutics PLC
LSE:AREC

Watchlist Manager
Arecor Therapeutics PLC
LSE:AREC
Watchlist
Price: 77.6 GBX 4.86%
Market Cap: 29.3m GBX

Arecor Therapeutics PLC
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Arecor Therapeutics PLC
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Arecor Therapeutics PLC
LSE:AREC
Cash from Operating Activities
-ÂŁ9.2m
CAGR 3-Years
-19%
CAGR 5-Years
-103%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash from Operating Activities
-$142.1m
CAGR 3-Years
-2%
CAGR 5-Years
-89%
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash from Operating Activities
-$239.7m
CAGR 3-Years
-54%
CAGR 5-Years
-108%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash from Operating Activities
ÂŁ26.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash from Operating Activities
ÂŁ67.2m
CAGR 3-Years
25%
CAGR 5-Years
2%
CAGR 10-Years
7%
Oxford BioMedica PLC
LSE:OXB
Cash from Operating Activities
-ÂŁ7.8m
CAGR 3-Years
28%
CAGR 5-Years
-6%
CAGR 10-Years
3%
No Stocks Found

Arecor Therapeutics PLC
Glance View

Market Cap
29.3m GBX
Industry
Biotechnology

Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The company partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to their products under a technology licensing model. These products can be at any stage in development from early phase clinical development through to products that are already on the market. The areas of applications of the technology are biologicals, biosimilars, therapeutic vaccines and therapeutic peptides.

AREC Intrinsic Value
20.08 GBX
Overvaluation 74%
Intrinsic Value
Price
A

See Also

What is Arecor Therapeutics PLC's Cash from Operating Activities?
Cash from Operating Activities
-9.2m GBP

Based on the financial report for Dec 31, 2024, Arecor Therapeutics PLC's Cash from Operating Activities amounts to -9.2m GBP.

What is Arecor Therapeutics PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-103%

Over the last year, the Cash from Operating Activities growth was -57%. The average annual Cash from Operating Activities growth rates for Arecor Therapeutics PLC have been -19% over the past three years , -103% over the past five years .

Back to Top